Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
53.86
-0.75 (-1.37%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 52.42 - 55.58
52 week 21.60 - 112.57
Open 54.11
Vol / Avg. 722,622.00/895,145.00
Mkt cap 3.44B
P/E     -
Div/yield     -
EPS -1.44
Shares 63.92M
Beta 1.29
Inst. own 88%
May 5, 2014
Q1 2014 Alnylam Pharmaceuticals Earnings Release (Estimated) Add to calendar
Apr 9, 2014
Alnylam Pharmaceuticals at Needham Healthcare Conference
Mar 13, 2014
Alnylam Pharmaceuticals at Barclays Healthcare Conference
Mar 4, 2014
Alnylam Pharmaceuticals at Cowen Health Care Conference
Feb 24, 2014
Alnylam Pharmaceuticals at Canaccord Genuity Orphan Drug One-on-One Day
Feb 13, 2014
Q4 2013 Alnylam Pharmaceuticals Earnings Conference Call
Feb 13, 2014
Q4 2013 Alnylam Pharmaceuticals Earnings Release
Feb 12, 2014
Alnylam Pharmaceuticals at Leerink Swann Global Healthcare Conference
Feb 11, 2014
Alnylam Pharmaceuticals at Biotechnology Industry Organization CEO & Investor Conference
Feb 6, 2014
Alnylam Pharmaceuticals at Emerald Research Groundhog Day Investment Forum
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -298.30% -189.17%
Operating margin -272.81% -197.05%
EBITD margin - -197.05%
Return on average assets -29.90% -25.20%
Return on average equity -45.70% -44.13%
Employees 115 -
CDP Score - -

Address

3rd Floor, 300 Third Street
CAMBRIDGE, MA 02142
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. (Alnylam) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). Its Alnylam 5x15, is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases. Its core programs in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-APC for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia, and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. In March 2014, the Company acquired Merck's wholly owned subsidiary Sirna Therapeutics, Inc.

Officers and directors

John K. Clarke Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Akshay K. Vaishnaw Ph.D,M.D. Executive Vice President, Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Laurence E. Reid Ph.D. Senior Vice President, Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 38
Bio & Compensation  - Reuters
Phillip A. Sharp Ph.D. Director
Age: 68
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Victor J. Dzau M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Marsha H. Fanucci Independent Director
Age: 59
Bio & Compensation  - Reuters